Next 10 |
home / stock / mitpf / mitpf news
Liege, Belgium, 28 May 2024 – 15:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that in the context of the monetization process and the uncertainties related thereto, Mithra postpones its Annual General Shareholdersȁ...
Liege, Belgium, 3 May 2024 – 17:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that, after diligent evaluation of several binding offers , Mithra has selected the offer submitted by Gedeon Richter, which relates to Es...
Mithra has received binding offers for selected assets, including Estetra SRL, as part of its monetization process. As it stands, the aggregate amount of these offers is insufficient to ensure full repayment of all creditors of Mithra, and, therefore, the offers do not allow to create value for M...
Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization. Approval of Judicial Reorganization Proceedings for Novalon SA, facilitating an amicable agree...
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early March Mithra is actively engaging with stakeholders Mithra will present its results for the full year 2023 on 8 March 2024 Liege, Belgium, 6 ...
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA ® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA ® in Israel on the signing of the final license and supply agreement Mithra is eligible t...
Mithra Completes Pediatric Study of ESTELLE ® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE ® to more women Potential EMA approval in pediatric population could lead to six-month extension of the Su...
Mithra Receives Positive DSMB Opinion on DONESTA ® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessment The menopause phase 3 program has previously reported positive top-line data; extension to Europe t...
Mithra receives guidance from the FDA for the DONESTA ® NDA marketing authorization filing in the United States DONESTA ® for the treatment of vasomotor symptoms of menopause, is expected to target the entire accessible US market of nearly 63 millio...
Mithra’s NEXTSTELLIS ® granted additional patent in the United States New patent extends protection for NEXTSTELLIS ® (ESTELLE ® ) until 2036 Mayne Pharma has a 20-year exclusive license and supply agreement in the US and...
News, Short Squeeze, Breakout and More Instantly...
Mithra Pharmaceuticals SA NV Company Name:
MITPF Stock Symbol:
OTCMKTS Market:
Liege, Belgium, 28 May 2024 – 15:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that in the context of the monetization process and the uncertainties related thereto, Mithra postpones its Annual General Shareholdersȁ...
Liege, Belgium, 3 May 2024 – 17:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that, after diligent evaluation of several binding offers , Mithra has selected the offer submitted by Gedeon Richter, which relates to Es...
Mithra has received binding offers for selected assets, including Estetra SRL, as part of its monetization process. As it stands, the aggregate amount of these offers is insufficient to ensure full repayment of all creditors of Mithra, and, therefore, the offers do not allow to create value for M...